Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the dose-response relationships of alogliptin, once
daily (QD) to an α-glucosidase inhibitor, three times daily (TID), to determine the optimal
clinical dose for type 2 diabetic patients.